Table 2 Number of patients who ever received a drug from onset to last available follow-up visit, with the corresponding days of drug exposure per medication from the first day of drug administration to the last available follow-up visit

DMARDs

Methotrexate

6963 (84.2%);

924 (449–1747)

3344 (83.8%);

494 (173–957)

1842 (61%);

1198 (555–2127)

Sulfasalazine

861 (10.4%);

360 (143–730)

274 (6.9%);

174 (32–470)

95 (3%)

443 (132–1042)

Cyclosporine

518 (6.3%);

616 (235–1358)

113 (2.8%);

186 (62–580)

16 (0.5%);

584 (250–1452)

Leflunomide

372 (4.5%);

434 (182–888)

219 (5.5%);

267 (68–701)

2 (0.1%);

840 (511–1169)

Hydroxychloroquine

279 (3.4%);

486 (202–1022)

106 (2.7%);

182 (1–535)

32 (1.1%);

957 (311–1612)

Azathioprine

108 (1.3%);

439 (187–973)

155 (3.9%);

186 (26–494)

31 (1%);

1171 (340–2179)

Thalidomide

35 (0.4%);

290 (85–665)

0

0

Systemic glucocorticoids

3299 (39.9%)

206 (67–648)

1680 (42.1%)

196 (81–449)

503 (16.7%)

91 (35–437)

Biologics

Etanercept

3600 (43.5%);

719 (300–1338)

2467 (61.8%);

489 (184–934)

726 (24%);

827 (341–1666)

Adalimumab

1778 (21.5%);

442 (174–927)

810 (20.3%);

350 (117–755)

657 (21.8%);

701 (292–1604)

Infliximab

705 (8.5%);

425 (160–951)

68 (1.7%);

213 (129–717)

189 (6.3%);

825 (328–1738)

Tocilizumab

633 (7.7%);

351 (126–742)

281 (7%);

377 (127–730)

122 (4%);

660 (193–1353)

Abatacept

420 (5.1%);

342 (156–715)

101 (2.5%);

190 (83–582)

80 (2.6%);

378 (164–1125

Anakinra

339 (4.1%);

299 (94–837)

50 (1.3%);

304 (9–806)

48 (1.6%);

422 (144–836)

Golimumab

161 (1.9%);

270 (106–623)

63 (1.6%);

344 (88–783)

93 (3.1%);

796 (370–1743)

Canakinumab

145 (1.8%);

351 (133–1032)

39 (1%);

364 (214–733)

7 (0.2%);

654 (604–1654)

Rituximab

103 (1.2%);

42 (24–87)

4 (0.1%);

15 (0–108)

20 (0.7%);

129 (15–1550)

Certolizumab

33 (0.4%);

166 (106–309)

4 (0.1%);

49 (0–110)

8 (0.3%);

984 (714–1538)

Other biologic agents

14 (0.2%);

217 (54–432)

4 (0.1%);

77 (25–149)

2 (0.1%);

325 (223–426)